7 I kliniske forsøg havde 99, 9% af initialt seronegative personer serokonverteret for både HPV type 16 og 18 1 måned efter 3. dosis.
In clinical trials, 99.9% of initially seronegative subjects had seroconverted to both HPV types 16 and 18 one month after the third dose.